LILLY ANTIBODY DRUG FAILS IN COVID-19 STUDY

27 oct 2020

LILLY ANTIBODY DRUG FAILS IN COVID-19 STUDY

The National institute of allergy and Infectious diseases, who sponsored for the study and for preparing the vaccine found that there are many safety issues and said that the drug would not prove helpful for hospitalized patients.

The US President Donald Trump was also experimental antibody drug from Regenro Pharmaceuticals Inc.on an emergency basis when was sickened with corona virus earlier this month. The company is continuously testing the drug in mild to moderately ill patients from preventing them from severe illness and with the partnership of a Canadian Company Abcellera.


Both the Lilly and Regenron have asked the US food and drug administration to grant permission for the drugs for covid-19. Lilly is not giving up and they are trying to prove that it is beneficial and whereas US Government is trying to put an end to the study.